The Federal Court of Australia has refused an appeal request in a decade-long case brought by Boehringer Ingelheim Animal Health against MSD subsidiary, Intervet International.
OptraHealth has filed a patent infringement lawsuit against Invitae that centres on the latter’s Gia chatbot that offers genetic testing and advice.
The Medicines Patent Pool and World Health Organization’s COVID-19 Technology Access Pool have signed a deal aiming to open up new technologies to people living in poorer countries.
The US Patent and Trademark Office has argued against a bid by medical device maker Arthrex, which wants recognition that an ex-interim acting director lacked the power to refuse to review its petition.
Roche subsidiary Spark Therapeutics has settled a lawsuit with rival gene-therapy company Bluebird Bio, which it had accused of infringing its “Spark” trademarks when marketing treatment for sickle-cell disease.
Natera has accused rival medical company CareDx of infringing two patents covering its “cell-free” DNA testing technology, Prospera.
Indian pharmaceutical company Emcure has asked a Washington court to toss a lawsuit accusing the company of stealing trade secrets related to a COVID-19 vaccine.
The US District Court for the District of Delaware has denied a motion from Beckman Coulter to stay an patent infringement lawsuit involving Sysmex Corporation until parallel proceedings at the US Court of Appeals for the Federal Circuit are concluded.
A subsidiary of Bristol-Myers Squibb has sued Chinese pharma company Jiangsu Hengrui Pharmaceuticals, alleging that the company’s planned generic of cancer medication Abraxane infringes a patent.
Novartis has convinced a Delaware court that a patent for its flagship multiple sclerosis treatment Gilenya is directed at patent-eligible matter, dismissing a challenge from Handa Pharmaceuticals that the patent is directed at natural phenomena and invalid.